Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder
A Cross-Sectional Study of 166 AQP4 Antibody–Seropositive Patients
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 18, 2020
- Accepted in final form February 2, 2021
- First Published April 20, 2021.
Author Disclosures
- Ilya Ayzenberg, MD (ilya.ayzenberg{at}rub.de),
- Daniel Richter, MD (daniel.richter-c34{at}ruhr-uni-bochum.de),
- Eugenia Henke, MD (eugenia.henke{at}rub.de),
- Susanna Asseyer, MD (susanna.asseyer{at}charite.de),
- Friedemann Paul, MD (friedemann.paul{at}charite.de),
- Corinna Trebst, MD (trebst.corinna{at}mh-hannover.de),
- Martin W. Hümmert, MD (huemmert.martin{at}mh-hannover.de),
- Joachim Havla, MD (joachim.havla{at}med.uni-muenchen.de),
- Tania Kümpfel, MD (tania.kuempfel{at}med.uni-muenchen.de),
- Marius Ringelstein, MD (marius.ringelstein{at}med.uni-duesseldorf.de),
- Orhan Aktas, MD (orhan.aktas{at}hhu.de),
- Brigitte Wildemann, MD (brigitte.wildemann{at}med.uni-heidelberg.de),
- Sven Jarius, MD (sven.jarius{at}med.uni-heidelberg.de),
- Vivien Häußler, MD (v.haeussler{at}uke.de),
- Jan-Patrick Stellmann, MD (jan-patrick.stellmann{at}univ-amu.fr),
- Makbule Senel, MD (makbule.senel{at}uni-ulm.de),
- Luisa Klotz, MD (luisa.klotz{at}ukmuenster.de),
- Hannah L. Pellkofer, MD (hannah.pellkofer{at}med.uni-muenchen.de),
- Martin S. Weber, MD (martin.weber{at}med.uni-goettingen.de),
- Marc Pawlitzki, MD (marc.pawlitzki{at}ukmuenster.de),
- Paulus S. Rommer, MD (paulus.rommer{at}meduniwien.ac.at),
- Achim Berthele, MD (achim.berthele{at}tum.de),
- Klaus-Dieter Wernecke, MD, PhD (wernecke{at}sostana.de),
- Kerstin Hellwig, MD (k.hellwig{at}klinikum-bochum.de),
- Ralf Gold, MD (ralf.gold{at}rub.de),
- Ingo Kleiter, MD;
- on behalf of the NEMOS (Neuromyelitis Optica Study Group)
- Ilya Ayzenberg, MD (ilya.ayzenberg{at}rub.de),
Roche, Alexion, Merck
NONE
Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Diamed
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel Richter, MD (daniel.richter-c34{at}ruhr-uni-bochum.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eugenia Henke, MD (eugenia.henke{at}rub.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Susanna Asseyer, MD (susanna.asseyer{at}charite.de),
NONE
NONE
Celgene, funding for travel to conference Alexion Pharma Germany GmbH, speaker honoraria Bayer Vital GmbH, speaker honoraria Roche Pharma AG, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD (friedemann.paul{at}charite.de),
Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Corinna Trebst, MD (trebst.corinna{at}mh-hannover.de),
NONE
NONE
Speaker honoraria (educational efforts, CME activities) from Alexion Pharma Germany GmbH, Biogen Idec/GmbH, Chugai Pharma Germany GmbH, MERCK, Novartis Pharma GmbH and Roche Pharma GmbH
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin W. Hümmert, MD (huemmert.martin{at}mh-hannover.de),
- Joachim Havla, MD (joachim.havla{at}med.uni-muenchen.de),
(1) Novartis Pharma (2) Merck Group (3) Roche (4) Sanofi Genzyme (5) Santhera (6) Biogen (7) Alexion
NONE
(1) Merck Group (2) Biogen (3) Novartis Pharma (4) Roche (5) Celgene
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
JH reports a grant for OCT research from Merck. JH reports a grant for PMS research from Merck.
I am (partially) funded by the German Federal Ministry of Education and Research (Grant Numbers 01ZZ1603[A-D] and 01ZZ1804[A-H] (DIFUTURE)).
NONE
Friedrich-Baur Foundation, Germany Guthy-Jackson Charitable Foundation, USA
NONE
NONE
NONE
NONE
NONE
NONE
- Tania Kümpfel, MD (tania.kuempfel{at}med.uni-muenchen.de),
- Marius Ringelstein, MD (marius.ringelstein{at}med.uni-duesseldorf.de),
1. Roche Pharma GmbH, served on a national scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
1. Novartis, funding for speaking at a conference. 2. Ipsen, funding for speaking at a conference. 3. Alexion, funding for speaking at a conference. 4. Roche, funding for speaking at a conference. 5. Bayer Healthcare, funding for travel to a conference. 6. Biogen Idec, funding for travel to a conference. 7. Genzyme, funding for travel to a conference. 8. TEVA, funding for travel to a conference. 9. Merz, funding for travel to a conference. 10. Merck, funding for travel to a conference.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD (orhan.aktas{at}hhu.de),
(1) Medimmune Scientific Advisory Board
NONE
(1) Bayer, speaker honoraria (2) Novartis, speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, speaker honoraria (6) Sanofi-Genzyme, speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen (2) Novartis
(1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), since 2016
(1) German Research Foundation (DFG), PI in GRK2578, since 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brigitte Wildemann, MD (brigitte.wildemann{at}med.uni-heidelberg.de),
Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche
NONE
Brigitte Wildemann has received personal fees from Alexion,Biogen, Merck Serono, Sanofi Genzyme, Novartis, and Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Brigitte Wildemann reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sven Jarius, MD (sven.jarius{at}med.uni-heidelberg.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vivien Häußler, MD (v.haeussler{at}uke.de),
- Jan-Patrick Stellmann, MD (jan-patrick.stellmann{at}univ-amu.fr),
Commercial - Genzyme Commercial - Alexion
NONE
Commercial Biogen - speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial - Genzyme
BMBF, German competence Network Multiple sclerosis (KKNMs). (FKZ 01GI1602c) 2016-2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Makbule Senel, MD (makbule.senel{at}uni-ulm.de),
MS has received consulting and/or speaker honoraria from Alexion, Bayer, Biogen, Merck, Roche, and Sanofi Genzyme. She has received research funding from the Hertha-Nathorff- Program.
NONE
She has received travel funding from Celgene, and TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Klotz, MD (luisa.klotz{at}ukmuenster.de),
(1) Genzyme (2) Novartis (3) Roche (4) Merck (5) Janssen (6) Alexion
NONE
(1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) Biogen, speaker honoraria and travel support (4) Roche, speaker honoraria and travel support (5) Genzyme, speaker honoraria and travel support (6) Teva, speaker honoraria and travel support (7) Janssen, speaker honoraria and travel support (8) Santhera, speaker honoraria and travel support (9) Grifols, speaker honoraria and travel support (10)Alexion, speaker honoraria and travel support (11)Bayer, speaker honoraria and travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Biogen (3) Merck (4) Immunic AG
(1) (CRC) SFB TR-128 Impact of dietary factors on the gut-CNS-axis  implications for CNS autoimmunity A08, Project leader, 2020-2024 (2) (CRC) SFB 1009 ÂImmune-cell interactions with endothelial cells and pericytes at the blood-brain- barrier: mechanisms and consequences A03, Sub-project Leader, 2020-2024 (3) Interdisciplinary Centre for Clinical Research, Münster (IZKF),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hannah L. Pellkofer, MD (hannah.pellkofer{at}med.uni-muenchen.de),
(1) Roche, Advisory board
NONE
(1) Biogen, Speakers honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin S. Weber, MD (martin.weber{at}med.uni-goettingen.de),
Evobrutinib Phase II steering committee
NONE
He received travel funding and/or speaker honoraria from Biogen-Idec, Merck Serono, Novartis, Roche, TEVA, Bayer and Genzyme.
Academic Editor for PLoS One
NONE
NONE
NONE
NONE
NONE
NONE
NONE
He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.
He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marc Pawlitzki, MD (marc.pawlitzki{at}ukmuenster.de),
NONE
NONE
Novartis, funding for travel to conference 2014-2016 Merck Serono, funding for travel to conference 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paulus S. Rommer, MD (paulus.rommer{at}meduniwien.ac.at),
19 Roche, Merck, Sandoz
NONE
NONE
Frontiers in Immunology, Guest Editor (Special Topic on Multiple Sclerosis: From Bench to Bedside, 2018/2019
NONE
NONE
NONE
1) Teva 2) Cellgene (only institutional)
NONE
Speaker honorary from ABBvie, Biogen, Daiichi-Sankyo, Merck, Novartis, Teva. Non of the disclosures results to a conflict of interest with regareds to the submitted manuscript
NONE
1) Merck 2) Roche 3) biogen 4) Amicus
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Achim Berthele, MD (achim.berthele{at}tum.de),
NONE
NONE
I received funding for travel and speaker honoraria from Alexion, Bayer Healthcare, Biogen, Genzyme, Merck Serono, Mylan,Novartis, Roche and Teva.
NONE
NONE
NONE
NONE
I have received consultancies from Alexion, Bayer Healthcare, Biogen, Celgene and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus-Dieter Wernecke, MD, PhD (wernecke{at}sostana.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kerstin Hellwig, MD (k.hellwig{at}klinikum-bochum.de),
(1) Novartis (2) Genzyme (3) Teva (4) Merck (5) Roche
NONE
(1) Biogen, funding for travel (2) Novartis, funding for travel (3) Merck, funding for travel (4) Biogen Idec Germany, speaker honoraria (5) Teva, speaker honoraria (6) Sanofi Genzyme, speaker honoraria (7) Novartis, speaker honoraria (8) Bayer Healthcare, speaker honoraria (9) Merck Serono, speaker honoraria (10) Roche, speaker honoraria
NONE
NONE
NONE
NONE
NONE
Honoraria from Biogen, Bayer Healthcare, Teva, Sanofi, Merck and Novartis
NONE
NONE
Biogen, Bayer Healthcare, Teva, Merck, Roche, Sanofi- Genzyme and Novartis
(1) Fund of the Federal Joint Committee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Gold, MD (ralf.gold{at}rub.de),
(1) TEVA Laquinimod DSMB, AbbVie, Celgene
NONE
Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering, Celgene, Novartis, Roche, Eisai
SAGE Journal TAND, Experimental Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
research support from Biogen, Genzyme, Merck and Novartis
NONE
NONE
NONE
From Roche From Merck From Bayer
NONE
NONE
NONE
NONE
NONE
- Ingo Kleiter, MD;
NONE
NONE
Alexion, Biogen, Novartis, Merck, Mylan, Sanofi Genzyme, Roche
Associate editor for BMC Neurology, editorial board member for Neuroimmunology Reports
NONE
NONE
NONE
Alexion, Biogen, Celgene, Chugai, IQVIA, Novartis, Merck, Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- on behalf of the NEMOS (Neuromyelitis Optica Study Group)
- From the Department of Neurology (I.A., D.R., E.H., K.H., R.G., I.K.), St. Josef-Hospital, Ruhr-University Bochum, Germany; Department of Neurology (I.A.), Sechenov First Moscow State Medical University, Russia; NeuroCure Clinical Research Center (S.A., F.P.), Charité Universitätsmedizin Berlin, Berlin Institute of Health, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany; Department of Neurology (C.T., M.W.H.), Hannover Medical School, Germany; Institute of Clinical Neuroimmunology (J.H., T.K., H.L.P.), University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Germany; Department of Neurology (M.R., O.A.), Medical Faculty, Heinrich Heine University Düsseldorf, Germany; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum Düsseldorf, Germany; Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany; Institut für Neuroimmunologie und Multiple Sklerose (INIMS) (V.H., J.-P.S.), Zentrum für Molekulare Neurobiologie, Hamburg, Germany; Klinik und Poliklinik für Neurologie (V.H., J.-P.S.), Universitätsklinikum Hamburg-Eppendorf, Germany; APHM (J.-P.S.), Hopital de la Timone, CEMEREM, Marseille, France; Aix Marseille Université (J.-P.S.), CRMBM, CNRS UMR 7339, Marseille, France; Department of Neurology (M.S.), University of Ulm, Germany; Münster Department of Neurology with Institute of Translational Neurology (L.K., M.P.), University Hospital Münster, Germany; Department of Neurology (H.L.P., M.S.W.), University Medical Center, Göttingen, Germany; Department of Neurology (M.P.), Otto-von-Guericke University, Magdeburg, Germany; Department of Neurology (P.S.R.), Medical University of Vienna, Austria; Neuroimmunology Section (P.S.R.), Department of Neurology, University of Rostock, Germany; Department of Neurology (A.B.), School of Medicine, Technical University of Munich, Germany; Charité-Universitätsmedizin Berlin, CRO SOSTANA GmbH Berlin (K.-D.W.), Germany; and Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany.
- Correspondence
Dr. Kleiter ingo.kleiter{at}rub.de
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Insufficient treatment of severe depression in neuromyelitis optica spectrum disorderVelina S. Chavarro, Maureen A. Mealy, Alexandra Simpson et al.Neurology: Neuroimmunology & Neuroinflammation, October 24, 2016 -
Articles
Pain in Guillain-Barré syndromeA long-term follow-up studyL. Ruts, J. Drenthen, J.L.M. Jongen et al.Neurology, September 22, 2010 -
Null Hypothesis
Insular and anterior cingulate cortex deep stimulation for central neuropathic painDisassembling the percept of painRicardo Galhardoni, Valquíria Aparecida da Silva, Luís García-Larrea et al.Neurology, April 05, 2019 -
Article
Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis opticaA pilot studyManabu Araki, Takako Matsuoka, Katsuichi Miyamoto et al.Neurology, March 14, 2014